Literature DB >> 21517709

Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions.

Nathaniel Katz1, Richard C Dart, Elise Bailey, Jeremiah Trudeau, Eric Osgood, Florence Paillard.   

Abstract

BACKGROUND: Transdermal and solid oral prescription opioid (PO) formulations can be abused by ingesting (with or without tampering), snorting, or injection (both requiring tampering).
OBJECTIVE: To determine the patterns of tampering with POs for abuse.
METHODS: Information was collected from published studies and databases.
RESULTS: Tampering with POs for abuse is common practice. Ingestion is the most prevalent method of abuse, followed by snorting and injection. From 1992 to 2002, injecting POs has decreased in favor of ingesting and snorting. Methods of abuse vary widely by product. Abuse methods with the highest morbidity are injection and inhalation.
CONCLUSIONS: The seriousness of health outcomes associated with tampering with POs warrants the development of PO formulations that prevent or deter tampering.

Mesh:

Substances:

Year:  2011        PMID: 21517709     DOI: 10.3109/00952990.2011.569623

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  46 in total

1.  Early Initiation of Substance Use as an Indicator of Problematic Substance Use Among Young Men Who Have Sex with Men (YMSM).

Authors:  Aleksandar Kecojevic; Corey H Basch; Stephen E Lankenau
Journal:  Subst Use Misuse       Date:  2017-08-04       Impact factor: 2.164

2.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

3.  Tamper-resistant drugs cannot solve the opioid crisis.

Authors:  Pamela Leece; Aaron M Orkin; Meldon Kahan
Journal:  CMAJ       Date:  2015-06-29       Impact factor: 8.262

Review 4.  Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.

Authors:  Tammi Schaeffer
Journal:  J Med Toxicol       Date:  2012-12

5.  Risk based in vitro performance assessment of extended release abuse deterrent formulations.

Authors:  Xiaoming Xu; Abhay Gupta; Manar Al-Ghabeish; Silvia N Calderon; Mansoor A Khan
Journal:  Int J Pharm       Date:  2016-01-16       Impact factor: 5.875

Review 6.  Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain.

Authors:  Yvette N Lamb; Karly P Garnock-Jones; Susan J Keam
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

7.  A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Douglas Y Shapiro; Sandra D Comer
Journal:  Addiction       Date:  2013-03-13       Impact factor: 6.526

8.  Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics.

Authors:  Jon E Zibbell; Rachel Hart-Malloy; John Barry; Lillian Fan; Colleen Flanigan
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

9.  Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia.

Authors:  Andrea L Schaffer; Nicholas A Buckley; Louisa Degenhardt; Briony Larance; Rose Cairns; Timothy A Dobbins; Sallie-Anne Pearson
Journal:  CMAJ       Date:  2018-03-26       Impact factor: 8.262

10.  Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics.

Authors:  David L Murphy; Jacob A Lebin; Stevan G Severtson; Heather A Olsen; Nabarun Dasgupta; Richard C Dart
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.